LOSS OF EFFECT OF ASPIRIN

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypotheses: 1)Inhibition by aspirin (ASA) of ex vivo induced platelet aggregation varies in a predictable time and dose dependent manner. (2)Thromboxane and Prostacyclin production is inhibited by ASA in a dose dependent manner and remains relatively constant over time once maximal inhibition has occurred. (3) Granule secretion by platelets during induced aggregation is inhibited by aspirin acutely but this effect does not persist during chronic administration at high